Metabolic Disorders

Post Menopausal Osteoporosis Global Clinical Trials Review, H1, 2018 Post Menopausal Osteoporosis Global Clinical Trials Review, H1, 2018

$2,500 | May 2018

GlobalData's clinical trial report, “Post Menopausal Osteoporosis Global Clinical Trials Review, H1, 2018" provides an overview of Post Menopausal Osteoporosis clinical trials scenario. This report provides top line data relating to the clinical trials on Post Menopausal Osteoporosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...

Diabetic Foot Ulcers Treatment Market Size, Share and Trends Analysis by Region, Treatment (Biologics, Wound Care Dressings, Therapy Devices, and Others), Ulcers Type (Neuro-ischemic Ulcers, Neuropathic Ulcers, and Ischemic Ulcers), End-user (Homecare Settings, Hospitals and Specialty Clinics, Others) and Segment Forecast, 2022-2027 Diabetic Foot Ulcers Treatment Market Size, Share and Trends Analysis by Region, Treatment (Biologics, Wound Care Dressings, Therapy Devices, and Others), Ulcers Type (Neuro-ischemic Ulcers, Neuropathic Ulcers, and Ischemic Ulcers), End-user (Homecare Settings, Hospitals and Specialty Clinics, Others) and Segment Forecast, 2022-2027

$3,950 | November 2022

The diabetic foot ulcers market size was valued at US$ 4.74 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 7.1% during 2022-2027. The key to the growth has been the rising prevalence of diabetes and resulting increase in incidence of diabetic foot ulcers. Additionally, rise in geriatric population, and increasing adoption of novel biologics and wound care devices for treatment, favoring diabetic foot ulcers market growth.

Obesity: Competitive Landscape to 2026 Obesity: Competitive Landscape to 2026

$3,495 | October 2018

Obesity is a preventable chronic condition, defined as abnormal or excessive fat accumulation characterized by raised body mass index (BMI ≥30), which is a major risk factor for chronic diseases such as cardiovascular diseases (CVD), diabetes, musculoskeletal disorders, and several major cancers. This report provides an assessment of the pipeline, clinical, and commercial landscape of Obesity. Overall, GlobalData expects that the approval of new long-acting GLP-1R and dual GLP-1R/GCGR agonists, and a novel appetite reducing drug will drive Obesity market...